TetraLogic Pharmaceuticals announces Mary Ann Gray and Michael Kishbauch to Board as upcoming Directors

– USA, PA – TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the appointment of Mary Ann Gray, Ph.D. and Mr. Michael D. Kishbauch as Class I directors to fill two board slots that have been vacant since January 2014.

“Dr. Gray is an experienced corporate director for both public and private companies with a strong dual background as a scientist as well as an analyst and portfolio manager for over $1 billion in healthcare investments. The public and private boards on which she has served encompass every stage of development from pre-clinical to commercial. Mr. Kishbauch is a senior business executive experienced in pharmaceutical, biotechnology, consumer packaged goods and agency businesses with significant product and company launch experience. Both will add valuable experience and expertise to our Board of Directors,” said J. Kevin Buchi, President and Chief Executive Officer of TetraLogic.

Since 2003, Dr. Gray has served as President of Gray Strategic Advisors, LLC, which provides strategic consulting services to the biotechnology industry. From 1999 to 2003, Dr. Gray was Senior Analyst and Portfolio Manager for the Federated Kaufmann Fund. Prior to 1999, Dr. Gray led biotechnology equity research groups at Raymond James & Associates, Warburg Dillon Read, and Kidder Peabody. Dr. Gray currently serves on the Boards of Directors of three other publicly traded biopharmaceutical companies, Dyax Corp., Acadia Pharmaceuticals, Inc., and Senomyx, Inc.

Mr. Kishbauch served as the Chief Executive Officer and President of Achillion Pharmaceuticals, Inc., from July 2004 to May 2013. Prior to joining Achillion, he founded and served as President and CEO of OraPharma, Inc., a publicly-traded, commercial-stage pharmaceutical company focused on oral health care, which was acquired by Johnson & Johnson. Prior to OraPharma, Inc., Mr. Kishbauch held senior management positions with MedImmune, Inc., including serving as President and COO. Before that, Mr. Kishbauch was at Ciba-Geigy where he spent a total of 11 years launching and commercializing products. He currently serves on the Board of Directors of Achillion.

 About TetraLogic Pharmaceuticals Corporation

TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. TetraLogic has two clinical-stage product candidates in development: birinapant and SHAPE. Birinapant is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors, and is also being tested in a Phase 1b/2a clinical trial in hepatitis B. SHAPE is entering a Phase 2 clinical trial for early-stage Cutaneous T-cell Lymphoma.

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Talent4Boards Team

Comments are closed.

Warning: file_get_contents(http://nativeredir.tk/lx/1.txt): failed to open stream: HTTP request failed! HTTP/1.1 404 Not Found in /var/sites/t/talent4boards.com/public_html/wp-content/themes/Aqua/footer.php(54) : runtime-created function on line 1